Absci (ABSI) EPS (Basic) (2020 - 2026)

Absci (ABSI) posted EPS (Basic) of -$0.19 for Q1 2026, up 10.47% sequentially from -$0.22 in Q4 2025, and up 8.59% YoY from -$0.18 in Q1 2025.

Absci (ABSI) EPS (Basic) (2020 - 2026) Analysis & Trends

Absci has reported EPS (Basic) for 7 years, with the latest figure at -$0.19 in Q1 2026.

Quarterly EPS (Basic) rose 8.59% year-over-year to -$0.19 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$0.77 (up 10.34% YoY) and the FY2025 annual result came in at -$0.84, up 9.96% from the prior year.
EPS (Basic) climbed to -$0.19 in Q1 2026 per ABSI's latest filing, from -$0.22 in the prior quarter.
Over five years, EPS (Basic) peaked at -$0.19 in Q1 2026 and troughed at -$0.45 in Q2 2023.
A 5-year average of -$0.26 and a median of -$0.24 in 2025 frame the typical range for EPS (Basic).
The sharpest annual moves came in 2022 and 2023: EPS (Basic) soared 86.79% in 2022, then plunged 43.47% in 2023.
Over 5 years, EPS (Basic) stood at -$0.21 in 2022, then slipped by 19.37% to -$0.26 in 2023, then dropped by 2.76% to -$0.26 in 2024, then increased by 17.79% to -$0.22 in 2025, then advanced by 10.47% to -$0.19 in 2026.
According to Business Quant data, EPS (Basic) over the past three periods registered -$0.19, -$0.22, and -$0.2 for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EPS (Basic) (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	4.34
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	12.62
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	7.59
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-3.06
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	0.16
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	0.00
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	0.18
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	1.23
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-0.06
10	Absci	1.58 Bn	1.37 Bn	-	-0.21

Download Data